Stock Traders Purchase High Volume of Pulmonx Put Options (NASDAQ:LUNG)

Pulmonx Corporation (NASDAQ:LUNG) saw some unusual options trading activity on Thursday. Stock traders purchased 3,491 put options on the company. This represents an increase of 1,895% compared to the typical volume of 175 put options.

Analyst Ratings Changes

LUNG has been the topic of several research analyst reports. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a research report on Thursday, April 30th. Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research note on Monday, July 13th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $6.50.

Institutional Trading of Pulmonx

A number of institutional investors and hedge funds have recently modified their holdings of the company. ExodusPoint Capital Management LP acquired a new position in shares of Pulmonx in the fourth quarter valued at $4,312,000. Vestal Point Capital LP acquired a new stake in Pulmonx during the third quarter worth $1,345,000. Bank of America Corp DE boosted its stake in Pulmonx by 60.3% during the first quarter. Bank of America Corp DE now owns 1,166,826 shares of the company’s stock worth $1,505,000 after buying an additional 439,027 shares in the last quarter. Birchview Capital LP bought a new stake in Pulmonx in the 4th quarter valued at $554,000. Finally, Kotler Kevin bought a new stake in Pulmonx in the 4th quarter valued at $442,000. 91.04% of the stock is currently owned by institutional investors.

Pulmonx Stock Performance

NASDAQ LUNG opened at $1.61 on Friday. The company’s fifty day moving average is $1.41 and its two-hundred day moving average is $1.47. Pulmonx has a 52-week low of $1.13 and a 52-week high of $2.89. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.91 and a quick ratio of 4.04. The firm has a market capitalization of $68.01 million, a price-to-earnings ratio of -1.39 and a beta of 0.30.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 90.27%. The business had revenue of $22.76 million during the quarter, compared to analyst estimates of $22.72 million. Equities research analysts forecast that Pulmonx will post -1.13 EPS for the current year.

Key Pulmonx News

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Q2 results beat expectations: Pulmonx reported an adjusted loss of $0.24 per share, narrower than the consensus loss estimate of $0.28 and improved from a $0.38 loss a year earlier. Revenue reached $22.76 million, exceeding estimates of $22.39 million. Pulmonx Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Revenue outlook reaffirmed: Management maintained its fiscal 2026 revenue forecast of $90 million to $92 million, broadly in line with the $90.8 million analyst consensus. The company is also targeting approximately a 76% gross margin, which could support improving profitability if achieved. Pulmonx Reiterates 2026 Revenue Outlook
• Neutral Sentiment: Investor attention remains high: Pulmonx traded more than 4.8 million shares versus an average volume of roughly 489,000 shares. The company’s earnings call provided additional context on its second-quarter performance and 2026 plans. Pulmonx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Profitability remains a risk: Pulmonx continues to report substantial losses, including a negative net margin of approximately 60% and negative return on equity. Separately, traders purchased 3,491 put options, nearly 19 times typical daily volume, signaling heightened hedging or bearish speculation, although options activity alone does not confirm a change in fundamentals.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.